A year in longevity: investment perspectives

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

New funds, switching focus to longevity, Silicon Valley blue-bloods and preparing for IPO.

Over the past year, we’ve had the pleasure of speaking with some of Longevity’s key investors and have been delighted to see new funds opening-up and others turning their focus to Longevity.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Phil Newman

Editor-in-Chief

Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oyster surfaces with $60m and a tau degrader that travels light

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE